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Abstract: Background: Early diagnosis is an important factor to improve the survival of Invasive 
Cervical Cancer (ICC) patients. Molecular biomarkers such as micro RNA (miRNA) can be used in 
the early detection of ICC. The expression of miR-21 and miR-29a are deregulated in many types of 
human cancers.  
Objective: The aim of this study was to investigate the differences in miR-21 and miR-29a expres-
sion patterns in the Human Papilloma Virus (HPV) infection and various grades of cervical cancer 
among Iranian women. 
Methods: Small RNAs were extracted from positive for HPV, cervical cancer and healthy samples 
from 43, 50 and 46 individuals, respectively. Expression levels of miR-21 and miR-29a were ana-
lyzed by SYBR Green real-time RT-PCR using specific primers, and 5s rRNA as the internal refer-
ence gene.  
Results: Results have shown a significant increase in miR-21 and decrease in miR-29 in cancerous 
samples in comparison with the control groups (P < 0.0001). 
Conclusion: This study illustrated that miR-21 and miR-29a could be operated as an oncogene and 
tumor-suppressor in cervical cancer progression. More studies are needed to demonstrate the role of 
miR-21 and miR-29a as potential biomarkers for the diagnosis of cervical cancer in future investiga-
tions. 
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1. INTRODUCTION 
Cervical Cancer (CC) is the third most common cancer in 
women in the world [1]. This cancer is developed through 
pre-malignant lesions known as Cervical Intraepithelial Neo-
plasia (CIN) from grades I to III [1-4]. More than 85% of the 
CC take place in developing countries. High-risk regions are 
Africa, Southern Africa, South-Central Asia, South America 
and Middle Africa. The clinical, epidemiological and labora-
tory data have demonstrated that persistent Human Papillo-
ma Virus (HPV) infection is the main etiological agent in CC 
progression. However, other factors such as cellular, immu-
nological, genetic, epigenetic, and environmental factors can 
affect the ultimate final outcome of dysplastic changes [1, 5-9]. 
*Address correspondence to this author at the Department of Medical Epi-
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MicroRNAs (miRNAs), as endogenous non-coding 
RNAs with 18-25 nucleotides in length, are derived from 
coding or noncoding genes and have regulatory roles in cells 
[10, 11]. Based on their expression patterns in cancers, 
miRNAs categorize as either oncogenes or tumor suppressor 
genes [10, 12]. 
Recent studies have shown that various miRNAs have 
different expression in High Risk-HPV positive (HR-HPV) 
CC cells as compared with HPV-Negative CC cells or nor-
mal cervical tissues [10]. It has been demonstrated that HR-
HPVs have roles on down-regulation of tumor suppressor or 
up-regulation of oncogenic miRNAs. In this way, differential 
miRNAs expression can be identified during CC progres-
sion. miRNAs have been revealed to involve in cellular 
events, including cell proliferation, apoptosis, angiogenesis, 
immune responses and tumor invasion and metastasis [10]. 
HPV infection leads to the expression of viral proteins that 
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alters normal cell functions such as proliferation and differ-
entiation [12, 13]. The aberrant expression of these proteins 
in CC has been suggested to be used as biomarkers for CC 
detection in the early stage [10, 11]. Additionally, it has been 
found that encoded proteins by HR-HPV can affect miRNA 
expression inside the host cell [2]. Among the cancers, asso-
ciated-miRNAs, miR-21 and miR-29a have been suggested 
to be used as potential diagnostic and prognostic biomarkers 
in CC. 
MiR-21 genomic locus is located in the fragile site 
FRA17B within the 17q 23.2 chromosomal region, which is 
one of the HPV16 integration loci [10, 14]. Therefore, over-
expression of miR-21 in CC may be associated with HPV16 
integration [10, 14, 15]. One of the targets for miR-21 is the 
tumor suppressor PTEN that its down-regulation leads to 
over-expression of matrix metalloproteinases MMP2 and 
MMP9 which promote cellular migration and invasion. 
Over-expression of these MMPs is recognized in CC and 
causes invasive cancer. Two other proteins, which have been 
implicated in the suppression of tumor invasion and metasta-
ses are programmed cell death 4 (PDCD4) and maspin. It 
seems that miR-21 acts directly on the PDCD4 miRNA. 
Some of the studies showed that PDCD4 was down-
regulated in CC, indicating that miR-21 could play an onco-
genic role in CC invasion and metastasis [10]. 
MiR-29a is mapped to chromosome 7 and is down-
regulated in CC. MiR-29a decreases expression of Heat-
shock protein 47 (HSP47), which is a super-family of serine 
protease inhibitors. The over-expression of HSP47 has an 
important role in cancer development and metastasis pro-
cesses. On the other hand, miR-29a inhibits G1/S transition 
in cervical cell lines. The expression of this miRNA is down-
regulated during CC development and loading to apoptosis 
insensibility and uncontrolled cell cycles with increasing 
Ying Yang 1 (YY1) motif and CDK6 protein expression. 
YY1 is an important transcription factor that inhibits apopto-
sis and CDK6, is a kinase that phosphorylates pRb releasing 
the transcriptional factor E2F [12, 16]. It is known that miR-
29a targets the HPV-related genes. However, the molecular 
mechanisms through which HPV infection can down-
regulate miR-29a have not been well understood yet [17]. 
In the present study, expression levels of miR-21 and 
miR-29a in HPV infected individuals and CC patients in 
comparison with the healthy control groups in Iranian wom-
en investigated. 
2. MATERIALS AND METHODS 
2.1. Study Population 
In this study, 50 Liquid Based Cytology Samples (LBCs) 
samples were collected in 2012 at Mohebe-Yas Hospital, 
Tehran, Iran, from women diagnosed with Cervical Intraepi-
thelial Neoplasia (CIN) and Invasive Cervical Cancer (ICC). 
In addition, 46 archived LBC samples from patients with 
neither CC nor HPV infection, were collected to serve as a 
negative control. Also, 43 LBC samples that were positive 
for HPV were collected. Samples were selected from ar-
chived samples of several private pathobiology laboratories. 
The study was approved by the Shahid Beheshti University 
Ethic Committee. The informed consent form was obtained 
from cancer patients. Demographic and clinical data of pa-
tients were shown in Table 1. 
Table 1. Demographic clinical data of subjects. 
Data Set Women with CC 
Women with HPV Positive and 
Free of Cancer 
































HPV 16 & 18 positive 
Other HPV Genotypes* 
Pathological Stage of Neoplasia 
CIN I 
CIN II 






Total 50 43 46 
*Other HPV types including: High Risk HPV: 52, 31, 56, 58, 59, 33, 66, 45, 68, 35, 51, 39, 53, 82, 26.Low Risk HPV: 6, 11, 54, 61, 70 and 89. 
Abbreviations: CC, Cervical Cancer; HPV, Human Papilloma Virus; SD, Standard Division; CIN, Cervical Intra Neoplasia; ICC, Invasive Cervical Cancer  
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LBC samples were transferred to the Molecular Biology 
Department of Reference Health Laboratory, Iran Ministry 
of Health and Medical Education, Iran and stored at -20°C 
freezer for further use.  
2.2. miRNA Extraction and Evaluation 
The high pure miRNA Isolation Kit (Roche, Germany) 
was applied for purification of small RNAs (<100 nucleo-
tides) from the total RNA. The integrity of the miRNAs was 
checked using agarose gel electrophoresis stained with load-
ing dye. The extracted RNAs were used for cDNA synthesis 
immediately. 
2.3. cDNA Synthesis from Small RNA 
cDNA was synthesized using the miRNA amplification 
kit (Pars Genome Co, Iran). PCR primers for miR-21, miR- 
29-a and 5s-rRNA were obtained from Pars Genome Com-
pany, Iran. The 5s rRNA was selected as the internal refer-
ence gene. According to the manufacturer’s instructions, in 
the first step for poly-A tail synthesis: 10μl of small RNA 
(final conc. / amount: 1.5μg), was incubated with 2μl 10x 
reaction buffer, 1 μl ATP (final conc. / amount: 10Mm), 0.5 
μl poly-A enzyme, and 6.5μl DEPC treated water and was 
incubated at 370C for 10 min. In the second step, for specific 
cDNA synthesis, 5μl RNA poly A tail (final conc. / amount: 
1.5 μg) was mixed with 2μl 5x buffer, 0.5 μl reverse tran-
scriptase enzyme, 0.5 μl of each miRs cDNA synthesis spe-
cific primer (final conc. / amount: 15pmol), and 1μl dNTPs 
(final conc. / amount: 10mM). The mixture was incubated in 
a thermal cycler at 44 OC for 60 min, the process was fol-
lowed by one-minute inactivation of reverse transcriptase in 
85°C. Finally, obtained cDNAs were stored at -20°C until 
later use. 
2.4. Real-time RT-PCR 
Real-time RT-PCR was performed using the Rotor-gene 
(Corbett) instrument. Reactions were carried out in a total 
volume of 20μl, including 10μl SYBR green master mix 
(Takara, Japan), 0.5μl forward and reverse mix primer (final 
conc./ amount: 10pmol), 8.5 μl nuclease-free water, and 1μl 
undiluted cDNA. All samples were performed in duplicate 
using PCR cycling Rotor-Gene Q (software version 2.3) with 
the initial denaturation at 95°C for 5 minutes, followed by 40 
cycles of amplification at 95°C for 5 seconds, 61°C for 20 
seconds, and 72°C for 30 seconds. ∆CT method was used for 
analysis of real-time RT-PCR results. Mean of Cycle 
Threshold (CT) values were calculated for the reference gene 
and each of miRNAs. Threshold (CT value) was determined 
as the number of PCR cycle in which the fluorescent signal 
crosses the threshold. ∆CT is the difference of CT values of 
each miRNA and the reference gene. 2
-∆CT 
which is consid-
ered as an expression of two studied miRNAs between can-
cerous and free of cancer group was used. 
2.5. Statistical Analysis 
Differences in the mean between miRNAs (miR-21 and 
miR-29a) expression and ∆CT in the subjects of cervical 
cancer group, HPV-Positive and healthy individuals were 
analyzed using unpaired-t-test (Mann-Whitney test). In addi-
tion, differences in mean between miRs expression in CIN I 
& CIN II group and CIN III & ICC group were analyzed. 
Statistical analysis was performed with Graph Pad Prism 
version 7. P-value < 0.05 was considered as significant level. 
3. RESULTS 
3.1. miR-21 Expression in Unpaired Case and Control 
Samples 
The miR-21 was significantly up-regulated in CC sam-
ples compared with HPV-Negative control group 
(P<0.0001). Level of miR-21 expression in these groups is 
shown in Fig. (1A). The mean of ∆CT value for miR-21 in 
CC sample was 5.02 ± 0.7299 in comparison with 8.184 
±5.419 in HPV-Negative control samples (P< 0.0001). 
The miR-21 was up-regulated in HPV-Positive samples 
compared with controls, but it was not significant 
(P=0.2075). Level of miR-21 expression in population study 
is shown in Fig. (1B). The mean of ∆CT value for miR-21 in 
HPV-Positive samples was 10.27 ± 5.879 as compared with 
7.780±4.824 in controls. (P=0.0590). 
The relative expression of miR-21 was compared in CC 
progression. The number of patients with CIN I & CIN II 
and CIN III &ICC was 15 and 35, respectively. Our study 
showed that miR-21 was up-regulated in CIN III & ICC 
group compared to CIN I & CINII, however, it was not sig-
nificant. (P = 0.5879) (Fig. 1C). The mean of ∆CT value for 
miR-21 in CINIII & ICC was 19.43 ± 6.094 as compared 
with 18.92±3.344 in CIN I & CIN II (P = 0.8853). 
3.2. miR-29a Expression in Unpaired Cases and Control 
Samples 
The miR-29a was significantly down-regulated in CC 
samples compared with controls (P < 0.0001). The expres-
sion level of miR-29a in controls and CC samples is shown 
in Fig. (2A). The mean of ∆CT value for miR-29a in CC 
samples was 20.08±6.137 in comparison with 5.221±0.7698 
in HPV-Negative control samples (P < 0.0001). The miR-
29a was down-regulated in HPV-Positive samples compared 
to healthy controls, however, it was not significant (P= 
0.3624). The expression level of miR-29a in control and 
HPV-Positive from 46 and 43 individuals are shown in Fig. 
(2B). The mean of ∆CT value for miR-29a in HPV positive 
samples was 11.56 ± 5.385 in comparison with 10.38±5.241 
in free of cancer samples (P = 0.3200).  
Furthermore, the relative expression of miR-29a was 
compared in CC progression. Women suffered from CIN I & 
CINII and CINIII & ICC were 15 and 35, respectively. The 
miR-29a was down-regulated in CINIII &ICC patients com-
pared with CIN I & CINII, however, it was not significant 
(P= 0.3818) (Fig. 2C). The mean of ∆CT value in CINIII& 
ICC individuals was 22.02 ± 4.717 in comparison with 19.88 
± 4.309 in CIN I& CINII individuals (P = 0.2697). 
4. DISCUSSION 
Cervical Cancer (CC) as a genetic and pathologic com-
plex disorder and de-regulation in the miRNA expression has 
a significant biological role in the malignancy [5, 10]. Sever-
al studies have shown that de-regulation of miRNA was de-
tected in CC patients; it would appear these molecules could 
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Fig. (1). (A): Relative expression levels of miR-21 in cancerous and control group (P < 0.0001). (B): Relative expression levels of miR-21 in 
HPV-Positive and control group (P = 0.2075). (C): Relative expression levels of the miR-21 in CIN I, II, III& ICC group (P= 0.5879). 
 
Fig. (2). (A): Relative expression levels of miR-29a in cancerous control group (P < 0.0001). (B): Relative expression levels of the miR-29a 
in control and HPV positive group (P= 0.3624). (C): Relative expression levels of the miR-29a in CIN I, II, III & ICC group (P= 0.3818). 
be used as potential biomarkers. Other studies indicated 
some interactions between viral oncoproteins and miRNAs 
like miR-21 and miR-29a. It would appear that deregulated 
miRNAs have crucial roles in cervical tumor biology [17-
19]. In order to explore the expression profile of miR-21 and 
miR-29a, a real-time quantitative RT-PCR has been carried 
out in HPV-Positive, HPV-Negative and CC samples. 
MiR-21 up-regulation can be played a major role in CC 
progression by affecting cell proliferation, tumor invasion, 
metastasis, angiogenesis, immune responses and apoptosis 
inhibition [10]. 
Our findings suggested that the miR-21 expression is 
significantly increased in CC cells in comparison with nor-









































































114     MicroRNA, 2019, Vol. 8, No. 2 Zamani et al. 
et al, and Chamsai Pientong et al. studies [18, 19]. Further-
more, we assessed the expression of miR-21 in HPV infected 
cells with no evidence of carcinogenic changes. Our results 
demonstrated that miR-21 expression was increased in the 
HPV-Positive group compared to the normal group. Even 
though, it was not significant. It would seem a comparison of 
miR-21 expression in different grades of dysplasia showed 
an up-regulation of miR-21 in CIN III& ICC in comparison 
of CINI & CINII, although it was not significant as well. 
A number of studies showed the biological role of miR-
29a in cellular processes such as angiogenesis, immune re-
sponses and pro-apoptosis in CC progression. Furthermore, 
it was demonstrated that miR-29a is the most highly down-
regulated miRNA in the clinical samples, indicating miR-29a 
as a putative tumor suppressive miRNA in human cancers 
[3]. 
At the present study, miR-29a expression was signifi-
cantly decreased in CC group comparing to the normal group 
which is consistent with the finding of Naohiko Seki et al. 
[9]. miR-29a expression was down-regulated in the HPV 
positive groups compared with the normal group, but it was 
not significant. Comparing expression levels of miR-29a in 
the CIN I& CIN II group and the CIN III& ICC group 
showed a reduced miR-29a expression in CIN I & CIN II, 
but it was not significant. 
CONCLUSION 
In conclusion, expression analysis of miR-21 and miR-
29a in HPV-Positive and CC samples in Iranian women is a 
novel approach in this study. There were no significant de-
regulation of these miRNAs among HPV-Positive free can-
cer and normal groups. The results demonstrated considera-
ble de-regulation in miR-21 and miR-29a in the cancerous 
group which was statistically significant. It seems that these 
miRNAs can be used as biomarkers for early detection of 
CC. In order to provide necessary information on the critical 
role of miRNAs as a prognostic marker in CC prevention 
programs, more studies are required to determine their spe-
cific function, transcriptional targets, and mechanisms of 
regulatory actions on cellular processes and HPV related 
changes in CC in comparison to normal cervical cells as 
well. 
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